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Abstract
Background: Diabetes mellitus is a disease lack of insulin, which has severely delayed and impaired wound healing
capacity. In the previous studies, various types of scaffolds and growth factors were used in impaired wound
healing. However, there were several limitations to use them such as short half-life of growth factors in vivo
and inadequate experimental conditions of wound-dressing material. Thus, our study aimed to determine the
biocompatibility and stability of the matrix containing structurally stabilized epidermal growth factor (S-EGF)
and basic fibroblast growth factor (S-bFGF).
Results and Discussion: We stabilized EGF and bFGF that are structurally more stable than existing EGF and
bFGF. We developed biocompatible matrix using S-EGF, S-bFGF, and hyaluronate– collagen dressing (HCD)
matrix. The developed matrix, S-EGF and S-bFGF loaded on HCD matrix, had no cytotoxicity, in vitro. Also, these
matrixes had longer releasing period that result in enhancement of half-life. Finally, when these matrixes were
applied on the wound of diabetic mice, there were no inflammatory responses, in vivo. Thus, our results demonstrate
that these matrixes are biologically safe and biocompatible as wound-dressing material.
Conclusions: Our stabilized EGF and bFGF was more stable than existing EGF and bFGF and the HCD matrix
had the capacity to efficiently deliver growth factors. Thus, the S-EGF and S-bFGF loaded on HCD matrix had
improved stability. Therefore, these matrixes may be suitable for impaired wound healing, resulting in
application of clinical treatment.
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Background
The wound healing process consists of inflammation,
contraction, neoangiogenesis, extracellular matrix depos-
ition, granulation tissue synthesis, re-epithelialization and
remodeling. These stages are related in various cellular
and molecular signals [1] and when these signals are
impaired, the wound healing process is delayed. This
phenomenon is caused by the various form of host impair-
ment such as malnutrition, infection and diabetes [2].
Recently, several studies have reported that the growth
factors, as therapeutical agents, are widely used in im-
paired wound healing [3, 4]. Platelet derived growth
factor (PDGF), basic fibroblast growth factor (FGF)
and epidermal growth factor (EGF) have been most
prevalently studied growth factors [5–7]. Indeed, these
growth factors are known as stimulating cell prolifera-
tion, recruiting various cell types into injured site, and
inducing synthesis of extracellular matrix during
wound healing process [8–10]. Particularly, the bFGF
has ability to promote the wound repair and angiogen-
esis [11–13] and the EGF contributes to the wound
healing via stimulating proliferation and migration of
keratinocytes and also facilitating dermal regeneration,
in vivo [8].
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Although these growth factors have therapeutic effects
in diabetic wound healing, they have been limited to use
as therapeutic agents due to the short half-life of growth
factors, in vivo. Indeed, the inadequate experimental
conditions that did not continuously release growth
factors from scaffolds and lose their activity readily
when they are loaded onto various types of scaffolds [7,
14–17]. Thus, the new approaches are required for the
stable delivery of growth factors locally into the im-
paired wounds.
There have been variety types of scaffolds such as col-
lagen sponge [18], photo-crosslinking chitosan hydrogel
[19] and gelatin sponge [20] which were used to deliver
bFGF and EGF onto the diabetic wounds. However,
these scaffolds had certain unsatisfied features including
rapid absorption and poor mechanical strength [21, 22].
To compensate the shortcomings of the existing wound-
dressing materials, the development of new wound-
dressing material is necessary.
The hyaluronate- collagen dressing (HCD) matrix has
been already used as wound-dressing materials because
of advantages such as haemostatic effect, reduction of
pain, maintenance of moisturizing condition, and feas-
ible to exchange the wound dressing material because
the surface of the HCD matrix does not adhere to
wound. For these reason, we considered that HCD
matrix is suitable for base material. So, we have
assessed the biocompatibility and stability of modified
growth factor-loaded HCD matrix, in vitro. Further-
more, we investigated in vivo stability of modified
growth factors-loaded HCD matrix, via application on
the diabetic mice.
Methods
Materials
Hyaluronic acid (Shisheido, Shizuoka, Japan), Collagen
(Koken, Tokyo, Japan) and Pluronic F68 (Daebong LS,
Incheon, Korea) are base materials for production of
hyaluronate- collagen dressing (HCD) matrix. For the
production of HCD matrix, we first dissolved the 0.1 %
of collagen in refined water (pH3 ~ 4) and raised pH to
7 ~ 8 then dissolved 0.8 % of HA. The 0.1 % of F68 was
added to help blending collagen and HA then evenly
mixed them with homogenizer. Subsequently, we added
stabilized growth factors with concentrations of 0.1, 0.3,
1, and 2.5ug/cm2 and aliquot them into the mold for the
lyophilization (Additional file 1: Figure S1). For selection
of optimal sterilization method of S-EGF and S-bFGF,
we exerted various kinds of methods following ethylene
oxide (EO) gas, gamma irradiation (25 kGy) and elec-
tronic irradiation. The stabilized epidermal growth factor
(S-EGF) and basic fibroblast growth factor (S-bFGF) be-
came more thermostable through structural modification
when compared to existing growth factors. The stabilized
growth factor loaded HCD matrixes were received from
GENEWEL (Seongnam, Gyeonggi-do, Korea).
MTT Assay and cell proliferation assay
L929 cells (Sigma-Aldrich, St Louis, MO, USA) were
cultured in Dulbecco’s Modified Eagle’s Medium-high
glucose (DMEM; Gibco, Carlsbad, CA, USA) supple-
mented with 10 % FBS and 1 % penicillin/streptomycin
(P/S). The NIH/3T3 fibroblast cells (Sigma-Aldrich) and
Balb/3T3 fibroblast cells (Sigma-Aldrich) were cultured
in DMEM (Gibco) supplemented with 0.5 % bovine calf
serum (BCS) and 1 % P/S. These cells were incubated
at 37 °C incubator with 5 % CO2 and medium was
replenished every two days. Each of cells were seeded
at density of 1X105cells/well on 96 well plates and in-
cubated for 24 h. We classified the groups as negative
control (no treatment), positive control (latex glove ex-
tracted solution; ISO-10993-5) [23], S-EGF, S-bFGF,
and HCD matrix containing S-EGF and S-bFGF and
added them in medium and cultured for 48 h. The S-EGF
and S-bFGF are loaded on HCD matrix with the con-
centration of 0.1, 0.3, 1, and 2.5 μg/cm2. Then thyiazo-
lyl blue tetrazolium bormide (MTT, M2128-100MG,
Sigma-Aldrich) was added and incubated for 3 h. At
the indicated time, DMSO was added and absorbance
was read at 570 nm.
Agar overlay
L929 cells were seeded 4X105cells/well on 6well plate.
After 24 h of cultivation, medium were removed and
1.5 % agar (BD, Franklin Lakes, NJ, USA) diluted in dis-
tilled water was overlaid on the cells. After solidification
of agar, 0.01 % neutral red vital dye (Sigma-Aldrich) was
treated on medium and placed in dark 37 °C incubator
for 90 min. The sterilized paper discs (6 mm) containing
HA, were laid on agar and incubated in dark for 24 h.
After incubation, cytotoxicity was rated with decolorized
zone around the paper discs [24].
Enzyme-Linked Immunosorbent Assay (ELISA)
Each of disk-shaped HCD matrix containing 1 μg/cm2 of
S-EGF and S-bFGF (diameter of 10 mm) was immersed
in 10 ml of 0.1 % BSA (Sigma-Aldrich) dissolved in PBS
and incubated in shaking incubator at 37 °C with
15 rpm for 7 days. Thereafter, to determine the amount
of growth factors, these mixtures were diluted to 1/1000
and analyzed by ELISA kit (R&D system, St Cloud,
MN, USA). Also, to confirm concentration of released
S-EGF and S-bFGF from HCD matrix, we installed
matrices (diameter of 30 mm) in the Franz Cell and
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incubated in shaking incubator at 37 °C with 50 rpm.
Then, collected samples on day 1, 3, 7, 10, 14, 21 and
confirmed quantity of S-EGF and S-bFGF with ELISA
kit (R&D system).
Preparation of streptozotocin (STZ)-induced type1
diabetic mouse model
ICR mice (Male, aged 7 weeks) were purchased from
Orient Bio (Seongnam, Gyeonggi-do, Korea) and housed
in wire cage at 20–22 °C at a relative humidity of 40–50 %.
We used type1 diabetic mice, induced by intraperitoneal
(I.P.) injection of streptozotocin (STZ) (200 mg/kg body
weight; Sigma-Aldrich) dissolved in 0.05 M citrate buffer
(pH4.5). One week after induction of diabetes, blood
glucose levels were measured using OneTouch Select
meter (Johnson&Johnson, New Brunswick, NJ, USA).
The diabetic phenotype in animals was confirmed by
blood glucose levels over 300 mg/dL and maintained
for three weeks. The animal experiments were carried
out in accordance with guidelines set by the Department
of Laboratory Animal Resources, Yonsei University
College of Medicine and Seoul, Korea (Permit number =
2015-0190).
Biocompatibility test of S-EGF and S-bFGF loaded on HCD
matrix in type1 diabetic mouse model
STZ-induced type1 diabetic mice (Male, aged 9 weeks)
were anesthetized with I.P. injection of Zoletile (30 mg/
kg body weight) and Rumpon (10 mg/kg body weight).
The hair on the back of mouse was shaved and subse-
quently wiped with 70 % ethanol. A 10 mm diameter
full-thickness of skin wounds were created on the backs
of STZ-induced diabetic mice and fixed with a silicone
ring to prevent wound contraction. The groups are
classified as Defect control, HCD only, HCD+S-EGF
0.3 μg/cm2, HCD+S-EGF 1 μg/cm2, HCD+S-EGF
2.5 μg/cm2, HCD+S-bFGF 0.3 μg/cm2, HCD+S-bFGF
1 μg/cm2, HCD+S-bFGF 2.5 μg/cm2. After application
of matrix on wound site, Vaseline gauze (Covidien, St.
Louis, MO, USA) and Neo dressing (Everaid, Gangnam,
Seoul, Korea) were placed on matrix for the minimal
dehydration of wound sites. In each groups, twelve animals
were used.
Statistical analysis
Statistical analysis was performed via Student’s T-TEST
and ANOVA. The data was expressed as the mean ±
a
b
Fig. 1 The cytotoxicity stabilized growth factors were tested with various concentrations; 0.1 μg/cm2, 0.3 μg/cm2, 1 μg/cm2 and 2.5 μg/cm2 (a)
and proliferation rate of S-EGF and S-bFGF after sterilization via EO gas, gamma irradiation and electron irradiation (b)
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standard deviation (SD). Values of *p < 0.05, **p < 0.01
were considered statistically significant.
Results and discussion
Biological stability of S-EGF and S-bFGF
First, we performed cytotoxicity assay for the evaluation
of the biological stability of stabilized epidermal growth
factor (S-EGF) and basic fibroblast growth factor (S-
bFGF). All concentrations of S-EGF and S-bFGF have
no significance compared to negative control, indicating
that S-EGF and S-bFGF do not retain toxicity (Fig. 1a).
The result of sterilization, the gamma and electron ir-
radiated S-EGF and S-bFGF showed relatively high
proliferation rate compared to EO gas (Fig. 1b). We
selected gamma irradiation as our sterilization method
because it is better to assure product sterility and also
more penetrating than electronic irradiation [25]. The
S-EGF and S-bFGF were biologically stable.
Biological safety of HCD matrix
For biocompatibility of HCD matrix, we evaluated cyto-
toxicity of three base materials, respectively. The colla-
gen and F68 had more than 90 % of cell survival rate,
whereas more than 1 % of HA showed reduction of sur-
vival rate (Fig. 2a). Since the cytotoxicity of HA appears
to be the characteristics of viscoelasticity rather than
cytotoxicity [26, 27], we substituted MTT assay to agar
Fig. 2 The biocompatibility of base materials of HCD matrix, in vitro, was confirmed by cytotoxicity assay of base materials such as F68, collagen
and HA (a) and the HA was confirmed by agar overlay with various percentages; 0.5 %, 1 %, 1.5 %, and 2 % (b)
a b
Fig. 3 Characteristics of S-EGF and S-bFGF loaded HCD matrix. Amount of S-EGF and S-bFGF contained in HCD matrix was measured via ELISA
(a) and cumulative release of S-EGF and S-bFGF that are loaded on HCD matrix was measured by ELISA during 21 days (b)
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overlay test that is minimally influenced by viscoelasti-
city. All concentrations of HA showed no decolorized
zones, suggesting that HA had no toxicity (Fig. 2b).
These data indicate that there is no cytotoxicity in HCD
matrix as base material.
The capacity of S-EGF and S-bFGF loaded on HCD matrix,
and its cytotoxicity, in vitro
We evaluated the final concentration of S-EGF and
S-bFGF that are loaded on HCD matrix. As a result,
the concentrations were 89.44 ± 4.6 pg/ml and 85.27 ±
2.07 pg/ml, respectively (Fig. 3a). When we evaluated the
releasing period of growth factors from HCD matrix, the
growth factors were gradually released during long-term
period until day21 (Fig. 3b). Thus, this result demon-
strated the potential utility of HCD matrix as an agent
delivery scaffold.
Additionally, we determined the biological stability of
S-EGF and S-bFGF loaded on HCD matrix. Similar to
HCD group as a negative control, each concentration of
S-EGF and S-bFGF loaded on HCD matrix showed more
than 90 % of cell survival rate at all concentrations.
These results define the biological safety of our S-EGF
(Fig. 4a) and S-bFGF (Fig. 4b) loaded HCD matrix,
suggesting the optimal biocompatibility as wound-
dressing material.
The stability of S-EGF and S-bFGF loaded on HCD matrix,
in vivo
Next, we assessed the stability of S-EGF and S-bFGF
loaded on HCD matrix in vivo. These matrixes had no
inflammatory effect at day 7, indicating that the S-EGF
and S-bFGF loaded on HCD matrix is negligent as
wound-dressing material. In addition, the S-EGF and S-
bFGF loaded on HCD matrix showed slight acceleration
of wound healing when compared to defect control and
HCD matrix only group (Fig. 5a). As shown in Fig. 5b,
the wound areas of S-EGF group were decreased about
50 % compared with defect control group (Fig. 5b).
Thus, these results suggest that S-EGF and S-bFGF
loaded on HCD matrix is biologically safe to use as
wound-dressing material and have the potential in ac-
celeration of wound healing.
Taken together, our results demonstrated that S-EGF
and S-bFGF are more stabilized than existing EGF and
bFGF after modification, resulting in longer half-life and
releasing period of growth factors from HCD matrix, in
vitro. Indeed, this matrix was biologically safe, in vivo.
Although, the further studies toward S-EGF and S-bFGF
a b
Fig. 4 Cytotoxicity of HCD matrix containing S-EGF and S-bFGF was measured with various concentrations of S-EGF (a) and S-bFGF (b). Scale bar = 200 μm
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loaded on HCD matrix are needed to evaluate the effect-
iveness, in vivo, S-EGF and S-bFGF loaded on HCD
matrix is expected to be valuable wound-dressing mater-
ial in impaired wound healing.
Conclusions
For impaired wound healing, we developed the S-EGF
and S-bFGF loaded on HCD matrix, which has no effects
on cytotoxicity and proliferation. Also, we confirmed sta-
bility and releasing period of S-EGF and S-bFGF loaded
on HCD matrix. As a result, these matrixes showed more
stabilized and longer releasing period of growth factors
than existing EGF and bFGF, in vitro. Furthermore, when
these matrixes were applied on the wound of diabetic
mice, the inflammatory response was not occurred, indi-
cating that this matrix is biocompatible. According to
these results, the S-EGF and S-bFGF loaded on HCD
matrix may overcome the disadvantages of established
scaffolds in wound healing study. Taken together, the S-
EGF and S-bFGF loaded on HCD matrix may contribute
to the application in impaired wound healing because of
the biological safety.
Additional file
Additional file 1: Figure S1. The fabrication process of S-EGF and
S-bFGF loaded HCD matrix with collagen, HA, and F68. (PDF 42 kb)
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